Article

Customized LASIK provides measurable clinical and economic benefits

Lisbon, Portugal - A shift from conventional to wavefront-guided LASIK has resulted in reduced enhancement rates that translate into significant cost savings to the practice, said Richard L. Lindstrom, MD, adjunct professor emeritus, department of ophthalmology, University of Minnesota, and founding partner, Minnesota Eye Consultants, Minneapolis, United States.

Lisbon, Portugal - A shift from conventional to wavefront-guided LASIK has resulted in reduced enhancement rates that translate into significant cost savings to the practice, said Richard L. Lindstrom, MD, adjunct professor emeritus, department of ophthalmology, University of Minnesota, and founding partner, Minnesota Eye Consultants, Minneapolis, United States.

To evaluate the clinical and economic impact of wavefront-guided LASIK at Minnesota Eye Consultants, Dr. Lindstrom performed a retrospective study evaluating outcomes for two cohorts of patients treated over a 12-month period. The first group underwent conventional LASIK with a VISX laser between August 2001 and July 2002, and the second group was treated with customized LASIK using the VISX CustomVue system from August 2003 to July 2004. All patients treated during each period were included, and enhancement rates were calculated based on procedures performed during the 13-month period after the primary surgery.

For the conventional LASIK group, 62% of eyes achieved uncorrected visual acuity (UCVA) of 20/20 or better and the enhancement rate was 9.8%. With customized ablation, 91% of eyes achieved UCVA of 20/20 or better and the enhancement rate was cut nearly in half to 5.2%. Dr. Lindstrom estimated the reduced need for enhancement resulted in an approximate $100,000 savings for the practice.

“We believe there are many ways to reduce the enhancement rate still further. However, the enhancement rate for a more contemporary group of patients is probably even lower than 5.2% taking into account the current availability of customized treatment for patients with hyperopia, mixed astigmatism, and higher levels of myopia. Based on our experience, we have now become a 100% custom practice and perform the CustomVue procedure for any patient who is qualified for it,” said Dr. Lindstrom. He is a consultant to VISX.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.